Skip to main content
Springer Nature Link
Log in

WHO grade II and III meningiomas: a study of prognostic factors

  • Clinical Study - Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Meningiomas represent one of the largest subgroups of intracranial tumors. They are generally benign, but may show a histological progression to malignancy. Grades II and III meningiomas have been less well studied and are not well controlled because of their aggressive behaviour and recurrences. There is no consensus on therapeutic strategies and no prognostic factors are known. In order to determine these parameters, a multi-institutional retrospective analysis was performed in France with the support of the Neuro-Oncology Club of the French Neurosurgical Society. This study was performed on 199 adults treated for WHO grade II (166 patients) or grade III (33 patients) meningiomas between 1990 and 2004 in the Neurosurgery Departments of five French University Hospitals. Data on epidemiology, clinical behaviour and therapy were collected. Overall survival and progression-free survival were analysed as a function of each possible prognostic factor. For patients with grade II meningiomas, the 5- and 10-year OS rates were 78.4 and 53.3%, respectively, while, for patients with grade III meningiomas, the corresponding values were 44.0 and 14.2%. For patients with grade II meningiomas, the 5- and 10-year PFS rates were 48.4 and 22.6%, respectively, the corresponding values for patients with grade III meningiomas being 8.4 and 0%. For the grade II meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and Simpson 1 resection (P = 0.055) were associated with a longer OS. For the grade III meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and RT (P = 0.036) were associated with a longer OS. Histological grade II was found to be associated with a longer PFS (P = 0.0032) and RT reduced the PFS in grade II meningiomas (P = 0.0006) There were no other prognostic factors in terms of PFS for grades II and III meningiomas in univariate analysis. Multivariate analysis confirmed that age (< 60 years), Simpson 1 and histological grade II were independent prognostic factors for survival. This retrospective study might improve the management of grades II and III meningiomas. Prospective trials should delineate strong therapeutic guidelines for high-grade meningiomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Cushing HW, Eisenhardt LC (1938) Serial enumeration of meningiomas. In: Thomas CC (ed) Meningiomas their classification regional behavior, life history, and surgical end results. Thomas CC, Springfield, pp 56–73

    Google Scholar 

  2. Louis DN, Scheithauer BW, Budka H, Von Deimling A, Kepes JJ (2000) Meningiomas. In: Khleihues P, Cavenee WK (eds) WHO Classification of tumours pathology and genetics tumours of the nervous system. IARC, Lyon, pp 176–184

    Google Scholar 

  3. Perry A, Louis DN, Scheithauer BW, Budka H, Von Deimling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO Classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 164–172

    Google Scholar 

  4. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, Weber DC, Baumert BG, Canyilmaz E, Yalman D, Szutowicz E, Tzuk-Shina T, Mirimanoff RO (2008) Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients a multicenter, retrospective study of the rare cancer network. Int J Radiat Oncol Biol Phys 71:1388–1393

    Article  PubMed  Google Scholar 

  5. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24:E3

    Article  PubMed  Google Scholar 

  6. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89:1102–1110

    Article  CAS  PubMed  Google Scholar 

  7. Maier H, Ofner D, Hittmair A, Kitz K, Budka H (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77:616–623

    Article  CAS  PubMed  Google Scholar 

  8. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM (1993) Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 33:955–963

    CAS  PubMed  Google Scholar 

  9. Palma L, Celli P, Franco C, Cervoni L, Cantore G (1997) Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. Neurosurg Focus 2:e3

    Article  CAS  PubMed  Google Scholar 

  10. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046–2056

    CAS  PubMed  Google Scholar 

  11. Lusis E, Gutmann DH (2004) Meningioma: an update. Curr Opin Neurol 17:687–692

    Article  PubMed  Google Scholar 

  12. Whittle IR, Smith C, Navoo P, Collie D (2004) Meningiomas. Lancet 363:1535–1543

    Article  PubMed  Google Scholar 

  13. Perry A (2006) Meningiomas. In: Mc Lendon RE, Rosenblum MK, Bigner DB (eds) Russell & Rubinstein’s pathology of tumors of the nervous system, 7th edn. Hodder Arnold, London, pp 427–474

    Chapter  Google Scholar 

  14. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ko KW, Nam DH, Kong DS, Lee JI, Park K, Kim JH (2007) Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci 14:747–753

    Article  PubMed  Google Scholar 

  16. Modha A, Gutin PH (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538–550

    Article  PubMed  Google Scholar 

  17. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, Lu H, Carpenter LS, Chiu JK (1998) Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 37:177–188

    Article  CAS  PubMed  Google Scholar 

  18. Sioka C, Kyritsis AP (2009) Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 92:1–6

    Article  CAS  PubMed  Google Scholar 

  19. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120

    Article  PubMed  Google Scholar 

  20. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W (2006) Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 449:529–538

    Article  CAS  PubMed  Google Scholar 

  21. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095

    Article  PubMed  Google Scholar 

  22. Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH (2007) World Health Organization grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery 61:1194–1198

    Article  PubMed  Google Scholar 

  23. Burger PC, Scheithauer BW (2007) Tumors of the central nervous system, vol 4. Fascicle 7, AFIP ARP, Washington, pp 331–362

    Google Scholar 

  24. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225

    Article  PubMed  Google Scholar 

  25. Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275–286

    Article  PubMed  Google Scholar 

  26. Ho DM, Hsu CY, Ting LT, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94:1538–1547

    Article  PubMed  Google Scholar 

  27. Aguiar PH, Tsanaclis AM, Tella OI Jr, Plese JP (2003) Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics. Neurosurg Rev 26:221–228

    Article  PubMed  Google Scholar 

  28. Roser F, Samii M, Ostertag H, Bellinzona M (2004) The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 146(3):7–44

    Google Scholar 

  29. Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297–306

    Article  CAS  PubMed  Google Scholar 

  30. Ayerbe J, Lobato RD, de la Cruz J, Alday R, Rivas JJ, Gomez PA, Cabrera A (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma a multivariate analysis. Acta Neurochir (Wien) 141:921–932

    Article  CAS  Google Scholar 

  31. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, Bussiere MR, Ojemann R (2000) Management of atypical and malignant meningiomas: role of high-dose 3D-conformal radiation therapy. J Neurooncol 48:151–160

    Article  CAS  PubMed  Google Scholar 

  32. Marcus HJ, Price SJ, Wilby M, Santarius T, Kirollos RW (2008) Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg 22:520–528

    Article  CAS  PubMed  Google Scholar 

  33. Jääskeläinen J, Haltia M, Servo A (1986) A typical and anaplastic meningiomas: radiology surgery radiotherapy and outcome. Surg Neurol 25:233–242

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the Neuro-Oncology Club of the French Neurosurgical Society for its support, the Neurosurgical Departments of Angers, Lyon, Montpellier, Limoges and Paris Beaujon for the use of their patients’ data, the “Unité Fonctionnelle de Recherche Clinique et Biostatistiques” CHU Limoges for help with the statistics, Jacques Champier for reviewing the manuscript and Dr Tom Barkas for linguistic help.

Author information

Authors and Affiliations

  1. Department of Neurosurgery D, Groupement Hospitalier Est, Hôpital Neurologique Wertheimer, 69677, Bron, France

    Anne Durand, Robert Deruty & Jacques Guyotat

  2. Department of Neuropathology, CHU Dupuytren, 87000, Limoges, France

    François Labrousse

  3. Department of Neuropathology, Groupement Hospitalier Est, Hôpital Neurologique Wertheimer, 69677, Bron, France

    Anne Jouvet

  4. Department of Neurosurgery, Hôpital G. Chauliac, 34295, Montpellier, France

    Luc Bauchet

  5. Department of Neurosurgery, Hôpital Beaujon, 92118, Clichy, France

    Michel Kalamaridès

  6. Department of Neurosurgery, CHU, 49933, Angers, France

    Philippe Menei

  7. Department of Neurosurgery, CHU Dupuytren, 87000, Limoges, France

    Jean Jacques Moreau

  8. Inserm U482, Université de Lyon, Lyon1, UMR-S842, 69372, Lyon, France

    Anne Jouvet & Michelle Fèvre-Montange

Authors
  1. Anne Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Labrousse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Jouvet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luc Bauchet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michel Kalamaridès
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Philippe Menei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert Deruty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean Jacques Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michelle Fèvre-Montange
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jacques Guyotat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Durand.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durand, A., Labrousse, F., Jouvet, A. et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95, 367–375 (2009). https://doi.org/10.1007/s11060-009-9934-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9934-0

Keywords

Search

Navigation